Ray Therapeutics
Stub active Updated Apr 25, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
About
Ray Therapeutics is a Berkeley-based clinical-stage biopharmaceutical company developing gene therapies for vision restoration in patients with severe retinal degeneration 12. Founded in 2020, its lead clinical program RTx-015 received FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for retinitis pigmentosa 2. The April 2026 Series B was upsized and oversubscribed at $125M 13.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-04-21 | Series B | $125M | Janus Henderson Investors | 4BIO Capital, MSD Global Health Innovation Fund, Norwest Venture Partners, Versant Ventures, Casdin Capital 13 |
What Investors Say
No independently sourced investor quotes found.
What Founders Say
No independently sourced founder quotes found.
Sources
-
BusinessWire, “Ray Therapeutics Announces Upsized and Oversubscribed $125 Million Series B Financing for Vision Restoration Treatments,” April 21, 2026. https://www.businesswire.com/news/home/20260421096801/en/Ray-Therapeutics-Announces-Upsized-and-Oversubscribed-$125-Million-Series-B-Financing-for-Vision-Restoration-Treatments↩↩↩
-
Ray Therapeutics newsroom, “Ray Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RTx-015 in Retinitis Pigmentosa,” 2026, accessed April 2026. https://raytherapeutics.com/ray-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-rtx-015-in-retinitis-pigmentosa/↩↩
-
GlobeNewswire, “4BIO Capital portfolio company Ray Therapeutics announces upsized and oversubscribed $125 Million Series B financing for vision restoration treatments,” April 21, 2026. https://www.globenewswire.com/news-release/2026/04/21/3278149/0/en/4bio-capital-portfolio-company-ray-therapeutics-announces-upsized-and-oversubscribed-125-million-series-b-financing-for-vision-restoration-treatments.html↩↩